\n
\n <\/p>\n\n Please provide your email address to receive an email when new articles are posted on
.<\/p><\/div>\n<\/p><\/div>\n “
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nThe FDA approved a supplemental biologics license application for Asceniv, expanding its use to younger patients with primary humoral immunodeficiency, according to a press release.<\/p>\n
Prior to this approval, the release noted that the prescribing information for Asceniv (ADMA Biologics), a plasma-derived, polyclonal, intravenous immunoglobulin therapy, said it was only available for patients with primary humoral immunodeficiency aged at least 12 years. Now, it is available for patients aged at least 2 years.<\/p>\n
\n
Asceniv first received FDA approval in April 2019, according to the release.<\/p>\n
<\/p>\n
Kelli Williams<\/b><\/strong><\/p>\n<\/div>\n \u201cRespiratory viruses, especially RSV, have significant impact on our pediatric patients, particularly those with primary immunodeficiency (PI),\u201d Kelli Williams<\/b>, MD, MPH<\/b>,<\/b> section chief of pediatric allergy at Medical University of South Carolina, said in an email statement. \u201cThis often leads to ER visits, hospitalizations, missed school days and missed workdays for parents.<\/p>\n
\u201cThis new pediatric indication for Asceniv is exciting as it will offer a new treatment option for kids with PI that may improve their quality of life,\u201d she said.<\/p>\n
\n
\n
Sources\/Disclosures<\/h3>\n Source: <\/h2>\n
\n
Disclosures: <\/strong>
<\/p>\n
\n
\n
<\/p>\n
Ask a clinical question<\/strong> and tap into Healio AI’s knowledge<\/strong> base.<\/p>\n
<\/p>\nPubMed, enrolling\/recruiting trials, guidelines<\/li>\n
<\/p>\n
Clinical Guidance, Healio CME, FDA news<\/li>\n
<\/p>\n
Healio’s exclusive daily news coverage of clinical data<\/li>\n
\n <\/ul>\n
Learn more<\/button>\n <\/div>\n<\/div>\n